Sub B' contd

A1

3. (Amended) A composition according to claim 1, wherein the distressing substance is selected from the group consisting of emetics, nauseants and flavouring or bitter substances.

4. (Amended) A composition according to claim 3, wherein the distressing substance is selected from the group consisting of ergolides; quatenary ammonium compounds; non-permeant opioid antagonists; other opioid antagonists; emetics; and atropine or salts thereof.

5. (Amended) A composition according to claim 1, wherein the distressing substance is non-permeant and is incorporated in a vehicle being the same vehicle as for the opioid analgesic.

7. (Amended) A composition according to claim 1, wherein the opioid analgesic is selected from the group consisting of morphine, hydromorphone, buprenorphine, ketamine, fentanyl, tramadol, or pharmaceutically acceptable and percutaneously transmissible salts thereof.

8. (Amended) A composition according to claim 1 wherein the opioid analgesic is a narcotic opioid analgesic.

A2

9. (Amended) A composition according to claim 1, wherein the opioid analgesic is in an aqueous and/or alcoholic solution, or incorporated in a matrix including a pressure sensitive adhesive.

10. (Amended) A transdermal device containing a composition according to claim 1.

13. (Amended) A device according to claim 10, which is a monolithic patch.

A3

14. (Amended) A composition according to claim 1, which contains buprenorphine or pharmaceutically acceptable salt thereof as the opioid analgesic and atropine or pharmaceutically